Femasys CEO to Participate in Notable Summit
Femasys, Inc. (NASDAQ: FEMY), a pioneer in the biomedical field focused on addressing unmet health needs for women, is excited to announce that Kathy Lee-Sepsick, the company's Founder, President, and CEO, will engage in a highly anticipated fireside chat during the upcoming Maxim Healthcare Virtual Summit. This summit offers a unique platform for discussion on innovative health solutions and trends.
Details of the Fireside Chat
During this engaging session, Kathy Lee-Sepsick will discuss critical developments within Femasys and the broader health landscape for women. The fireside chat will feature discussions with Jason McCarthy, a respected figure in biotechnology research, serving as the Senior Managing Director and Head of Biotechnology Research at Maxim Group. This event will occur virtually from October 15 to 17, providing flexible access for participants, enabling attendance from anywhere.
Why This Event Matters
The Maxim Healthcare Virtual Summit plays a pivotal role in bringing together industry leaders to discuss key innovations in the health sector. Femasys, with its focus on creating accessible therapeutic and diagnostic solutions for women's health, will shine a light on how these innovations can make a difference. The summit is an invaluable opportunity for stakeholders to engage with thought leaders and share insights about the evolving landscape of healthcare.
Meet with Femasys Leadership
In addition to the fireside chat, Kathy Lee-Sepsick and Dov Elefant, the Chief Financial Officer, will be available for one-on-one meetings throughout the summit. This accessibility allows investors and interested parties to gain deeper insights into the company’s strategic vision and growth trajectory. Meetings can be scheduled to discuss potential collaborations or investments that align with Femasys's innovative approach and commitment to women's health.
About Femasys
Femasys is dedicated to enhancing women's health through a comprehensive portfolio of groundbreaking therapeutic and diagnostic products. The company's flagship offering, FemaSeed, is an FDA-cleared intratubal insemination device designed to optimize fertility treatments by delivering sperm directly to the site of conception. In addition, FemBloc, a non-surgical, permanent birth control method currently in advanced clinical development, aims to provide women with a safer and more cost-effective alternative to traditional surgical procedures. Femasys is also enhancing diagnostic capabilities with products like FemVue and FemCerv, which have received regulatory approval across various regions.
Continuous Innovation and Commitment
Femasys stands out for its commitment to innovation, ensuring its products are not only effective but also align with the needs of women around the globe. The company values in-house manufacturing and regulatory readiness, paving the way for successful commercial launches of its products. Through its extensive research and dedication to understanding women's health, Femasys is setting new standards and creating impactful solutions.
Frequently Asked Questions
What is the focus of the fireside chat at the summit?
The fireside chat will focus on key innovations and developments in women's health, led by Femasys's CEO, Kathy Lee-Sepsick.
When will the Maxim Healthcare Virtual Summit take place?
The summit is scheduled for October 15 to 17, 2024.
How can investors meet Femasys leadership?
Investors can schedule one-on-one meetings with Kathy Lee-Sepsick and CFO Dov Elefant throughout the summit.
What products does Femasys offer?
Femasys offers innovative solutions like FemaSeed for infertility treatment and FemBloc for permanent birth control.
Where can I find more information about Femasys?
For more information, you can visit the Femasys official website or follow their social media channels for updates.
